ferric citrate coordination complex

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Fexeric. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Fexeric.

For practical information about using Fexeric, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 17/11/2016

Authorisation details

Product details
Agency product number
Active substance
ferric citrate coordination complex
International non-proprietary name (INN) or common name
ferric citrate coordination complex
Therapeutic area (MeSH)
  • Hyperphosphatemia
  • Renal Dialysis
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Keryx Biopharma UK Ltd
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Riverbank House
2 Swan Lane
London EC4R 3TT
United Kingdom

Product information

12/10/2016 Fexeric - EMEA/H/C/003776 - IB/0007


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for treatment of hyperkalaemia and hyperphosphataemia

Therapeutic indication

Fexeric is indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD).

Assessment history

How useful was this page?

Add your rating
1 rating